about
Anti-Neutrophil Cytoplasmic Antibody Pathogenesis in Small-Vessel VasculitisDementia associated with the antiphospholipid syndrome: clinical and radiological characteristics of 30 patientsTyrosine kinase inhibitors for the treatment of rheumatoid arthritisAntiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients.Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome: clinical and haematological characteristics of 23 patients.Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus?Laboratory studies on pathophysiology of the catastrophic antiphospholipid syndrome.Antiphospholipid syndrome in Latin American patients: clinical and immunologic characteristics and comparison with European patients.Partial HELLP syndrome in pregnancy complicated by recurrent deep vein thromboses and palmar skin lesions in a patient with prothrombin gene 20210a mutation and antiphospholipid antibodies: an unusual case.Pregnancy and catastrophic antiphospholipid syndrome.Diagnosis and classification of the antiphospholipid syndrome.The use of chimeric vimentin citrullinated peptides for the diagnosis of rheumatoid arthritis.Racial/Ethnic variation in all-cause mortality among United States medicaid recipients with systemic lupus erythematosus: a Hispanic and asian paradox.Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients.Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome.The acute respiratory distress syndrome in catastrophic antiphospholipid syndrome: analysis of a series of 47 patientsRacial and Ethnic Differences in Mortality and Cardiovascular Events Among Patients With End-Stage Renal Disease Due to Lupus NephritisCatastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases.High prevalence of prothrombotic abnormalities in multifocal osteonecrosis: description of a series and review of the literature.Anti-chromatin (anti-nucleosome) antibodies.Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors.Lessons from the catastrophic antiphospholipid syndrome (CAPS) registry.Pregnancy and puerperium are high susceptibility periods for the development of catastrophic antiphospholipid syndrome.The catastrophic antiphospholipid (Asherson's) syndrome and malignancies.Association of discoid lupus erythematosus with other clinical manifestations among patients with systemic lupus erythematosus.Catastrophic antiphospholipid syndrome: lessons from the "CAPS Registry"--a tribute to the late Josep Font.Ilium osteitis as the main manifestation of the SAPHO syndrome: response to infliximab therapy and review of the literature.Anti-chromatin (anti-nucleosome) antibodies: diagnostic and clinical value.Diagnostic and prognostic value of antibodies against chimeric fibrin/filaggrin citrullinated synthetic peptides in rheumatoid arthritis.Infiltrating CD16+ Are Associated with a Reduction in Peripheral CD14+CD16++ Monocytes and Severe Forms of Lupus NephritisAntineutrophil cytoplasmic antibody-associated vasculitides and respiratory disease.Differences in synovial fluid cytokine levels but not in synovial tissue cell infiltrate between anti-citrullinated peptide/protein antibody-positive and -negative rheumatoid arthritis patients.Lung sarcoidosis induced by TNF antagonists in rheumatoid arthritis: a case presentation and a literature review.Therapeutic targeting of B cells for rheumatic autoimmune diseases.Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: report of 31 cases and review of the literature.B-cell depleting agents for ANCA vasculitides: a new therapeutic approach.Organ Damage and Quality of Life in Antiphospholipid Syndrome.Role of TWEAK/Fn14 signalling pathway in lupus nephritis and other clinical settings.IgG4-related disease: A concise review of the current literature.Distinct synovial immunopathology in Behçet disease and psoriatic arthritis.
P50
Q27490357-D66E358D-BEC4-4216-B0E7-EA4DFA9211F9Q28212959-6156CE64-7F7C-433C-BFEE-2B805B66835AQ28674280-198D35F7-CE27-4D47-9AF7-24255C80A64AQ33239982-4BA34B72-040C-456E-AC5C-30C576339CC9Q33366327-EE08E4F5-1832-4217-A02D-953B74D9C14FQ33367182-47B324AB-729E-4C86-BCC3-D02440CC8449Q33373456-8CE56B7D-0BBD-49AE-8D28-22B48808CCC9Q33375598-A59A414A-35B2-449D-A6B1-B4800C621D60Q33375774-32F0FDFD-77C6-4A57-84F0-5F19FD2BE68DQ33382266-D62AFE40-C3DD-4C14-B326-70B1DC47CB03Q33412887-E88D6620-D401-487B-81C5-CF3D9771CF68Q34043771-8468782D-FCD5-47A3-A392-B45C9B74C1D7Q35195820-4386A2C3-6F6C-45A8-B4D6-312DCC9D922CQ35553410-83DEB4CA-8498-4E8F-B893-8426AEFEDB80Q35555909-5C1E9849-2A62-42BB-BD9A-88B96A379624Q35636571-68C182E1-6D00-4D41-ABB5-21C955340DF1Q35890096-31A8D5A7-1195-4AA7-A9E8-CAFCF3B39163Q35953379-8F6E971C-6C44-4A98-ACF2-615712CDC61CQ36009039-C92DE12C-8182-44C8-93AA-424F0BAFBA3BQ36560777-32F0F9E8-481E-4C15-BC62-9F2318E5B0DBQ36670021-B2EF05A4-564F-4962-94D7-80C9892D4920Q36670025-763D4191-C3FC-4099-A46E-3C36A1EEBB90Q36670029-A8B0C3F3-A109-4FC6-8A40-83554140D0B2Q36670039-7D9E9054-1456-4179-B5A8-2D4783E58ACEQ36941224-955F57CD-D909-45AD-BD6D-B08F20A7F0AFQ36951067-379F47B3-E5AE-43B5-AA9B-938FA5EC55FEQ36988610-A1E4F9F5-E527-4BA8-BE56-A2562A8C380DQ37209078-8651E82A-39FE-4101-A21D-D398333CF5EAQ37453967-E04327D0-3C6A-4A2E-ABAF-386F211D993EQ37533350-DA67EE72-CDB1-4F38-A3E8-A693F5EE0685Q37609857-3BA0F2C9-0226-4DE5-B7B9-5EC78E94E490Q37690048-F133C2CE-DF68-4329-A1F7-4E6212A90388Q37773701-EDB9298D-C52F-4F12-98CD-1F3F7C0D14A7Q37829817-DAC27DA5-DBB5-43B2-84BF-C186C7DDBA43Q37875273-AA17D6EB-0832-4A12-B2A7-5B2DA1CE65D9Q37965313-5CD33F6A-2EB0-48DB-91E8-36BBC5CC41BDQ38697342-5BDC3D7D-2B92-4098-BDE8-E0CE9434E083Q38824240-9415459A-2C8C-4A13-954D-B3F83254D3B4Q38872478-5B25551B-E5A2-4EA5-96F8-37DC1E58D50DQ39872694-27BCBED0-7E23-42FF-B201-EAD53F790F88
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
José A Gómez-Puerta
@ast
José A Gómez-Puerta
@en
José A Gómez-Puerta
@es
José A Gómez-Puerta
@nl
José A Gómez-Puerta
@sl
type
label
José A Gómez-Puerta
@ast
José A Gómez-Puerta
@en
José A Gómez-Puerta
@es
José A Gómez-Puerta
@nl
José A Gómez-Puerta
@sl
prefLabel
José A Gómez-Puerta
@ast
José A Gómez-Puerta
@en
José A Gómez-Puerta
@es
José A Gómez-Puerta
@nl
José A Gómez-Puerta
@sl
P106
P1153
6603180858
P21
P31
P496
0000-0001-8177-702X